Rutgers University Study of the Genetics of Blood Cancers
The Rutgers University Study of the Genetics of Blood Cancers
The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.
研究概览
详细说明
This is an online research study to learn more about how genes affect your risk of blood cancers. No office visit is required and in return, participants may receive information about their genetic ancestry for free. This study will increase our understanding of the genetic basis of blood cancers, which is a crucial step in drug development to improve current treatment options. We seek a diverse population because diversity among participants maximizes the usefulness of the data. Participants will use our online study portal to answer questions about their health and provide their DNA via a saliva sample using a pre-paid mailer. Participation takes approximately 20 minutes. Participants will be invited to share data from their electronic health records, but this is not required for study participation. We keep participants engaged with short monthly newsletters.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Tara Matise, PhD
- 电话号码:848-445-3125
- 邮箱:rugcc-blood-cancer@rutgers.edu
学习地点
-
-
New Jersey
-
Piscataway、New Jersey、美国、08854
- 招聘中
- Rutgers University
-
接触:
- Tara Matise, PhD
- 电话号码:848-445-3125
- 邮箱:rugcc@rutgers.edu
-
首席研究员:
- Tara Matise, PhD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The study population consists of anyone at least 18 years old who lives in the United States, including both individuals who have or had blood cancer and those who have not. Participants include males, females, non-binary, and all race-ethnic groups.
描述
Inclusion Criteria:
- age 18 years or older
- currently living in the United States
- have access to the internet and a computer, laptop, tablet or smartphone
- willing to provide written informed consent for participation
- willing to provide DNA via a saliva sample using a collection kit mailed to your home
- willing to complete a survey with questions about health related to the study of blood cancer.
Exclusion Criteria:
- Not able to meet or fulfill any of the inclusion criteria
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:CROSS_SECTIONAL
队列和干预
团体/队列 |
|---|
|
Cases
Persons with blood cancer |
|
Controls
Persons who do not have blood cancer |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Genetic risk variants associated with blood cancer
大体时间:2 years
|
Genetic factors will be measured through whole exome sequencing and genome-wide genotyping array, and then correlated with blood cancer subtype. |
2 years
|
合作者和调查者
调查人员
- 首席研究员:Tara Matise, PhD、Rutgers University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- Pro2026000226
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Our study protocol does not include sharing IPD.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.